Long-time pick up 966.7%

Article Excerpt

C.R. BARD INC. $304 (New York symbol BCR; Conservative Growth Portfolio, Consumer sector; Shares outstanding: 72.3 million; Market cap: $22.0 billion; Price-to-sales ratio: 5.9; Dividend yield: 0.3%; TSINetwork Rating: Above Average; www.crbard.com) makes over 15,000 medical devices in four main areas: stents, catheters and other vascular products; oncology products that detect and treat various types of cancer; urology goods such as drainage and incontinence devices; and surgical tools. The stock jumped 20% in April 2017 after Bard accepted a takeover offer from rival medical device maker Becton Dickinson & Co. (New York symbol BDX). The combined firm will be in a better position to negotiate prices with increasingly large hospital-management companies. Under the terms of the offer, Bard investors will receive $222.93 in cash plus 0.5077 of a Becton share for each BCR share they hold. That would give Bard shareholders a 15% stake in the new company. Becton and Bard aim to complete the deal by the end of 2017. Based on Becton’s…